Paris, France, 1 April 2008 – Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, announced that the peer-reviewed medical journal ‘Clinical Cancer Research’ has today published positive pre-clinical in vivo efficacy and toxicology results concerning DTS-108. The research demonstrated that DTS-108 has greater anti-tumoral efficacy and safety, compared to irinotecan, as a result of an efficient and non-hepatic mode of activation. This leads to significantly higher circulating levels of the active metabolite with reduced gastrointestinal toxicity. In addition, it is anticipated that DTS-108 will bypass the inter-patient variability which is a major limitation in the therapeutic use of irinotecan. This is due to enhanced delivery of the active metabolite by using Diatos’ linker peptide technology, Vectocell®, which safe guards the efficacy whilst reducing the toxic side effects of the anti-cancer product... Diatos' Press Release -
Friday, April 25, 2008
Diatos : Pre-Clinical Results in Clinical Cancer Research
Paris, France, 1 April 2008 – Diatos SA, an international biopharmaceutical company focusing on the research, development and commercialization of targeted anti-cancer drugs, announced that the peer-reviewed medical journal ‘Clinical Cancer Research’ has today published positive pre-clinical in vivo efficacy and toxicology results concerning DTS-108. The research demonstrated that DTS-108 has greater anti-tumoral efficacy and safety, compared to irinotecan, as a result of an efficient and non-hepatic mode of activation. This leads to significantly higher circulating levels of the active metabolite with reduced gastrointestinal toxicity. In addition, it is anticipated that DTS-108 will bypass the inter-patient variability which is a major limitation in the therapeutic use of irinotecan. This is due to enhanced delivery of the active metabolite by using Diatos’ linker peptide technology, Vectocell®, which safe guards the efficacy whilst reducing the toxic side effects of the anti-cancer product... Diatos' Press Release -
